TargeGen, Inc. Selects Lead Drug for Clinical Development As A Topical (Eyedrop) Treatment For Wet Macular Degeneration and Other Eye Diseases
TargeGen, Inc., a biopharmaceutical company focusing on the development of small molecule drugs for the treatment of edema and angiogenesis related diseases, today announced that TG 100801, a potent, selective, and topically administered multi target kinase inhibitor, has been designated as a lead drug for clinical development in the treatment of major eye diseases including macular degeneration, diabetic macular edema and diabetic retinopathy. Current treatments for wet macular degeneration have demonstrated limited efficacy to date and require injection into the eye, thus increasing the risk of infection and retinal detachment.
© 2020 Pappas Capital, LLC. ALL RIGHTS RESERVED.